Tilray Brands (NASDAQ:TLRY – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.42), Zacks reports. The firm had revenue of $281.71 million for the quarter, compared to the consensus estimate of $246.30 million. Tilray Brands had a negative return on equity of 3.31% and a negative net margin of 156.51%.
Here are the key takeaways from Tilray Brands’ conference call:
- Record fiscal-year performance: Revenue rose 11% to $915.5 million, adjusted EBITDA increased 11% to $61.1 million, and fourth-quarter adjusted EBITDA reached a record $31.9 million. Management guided to fiscal 2027 adjusted EBITDA of $68 million to $75 million.
- International cannabis remained a major growth engine: Medical cannabis revenue grew 34% to $84.9 million, with notable growth in Germany, the U.K., Poland, and Italy. Portugal utilization reached approximately 80%, while the company said expanded supply and faster permitting could support further growth.
- BrewDog expanded Tilray’s beverage platform: The acquisition contributed $51.1 million of fourth-quarter revenue and adds more than $200 million in annualized revenue, pubs, and international distribution. Tilray also expects to begin brewing and distributing Carlsberg brands in the U.S. on January 1, 2027.
- Profitability remains under pressure in parts of the portfolio: International cannabis faced approximately $21.1 million of price compression, beverage gross margin declined to 36% from 39%, and the legacy U.S. beer business experienced industry headwinds and a 17% organic fourth-quarter revenue decline excluding BrewDog. Management is targeting cost reductions and margin expansion to address these issues.
- Balance-sheet flexibility improved, but cash generation is not yet positive after investments: Tilray ended the year with $234.6 million in cash, marketable securities, and restricted cash, while net debt fell to less than $1 million. However, adjusted free cash flow remained negative at $86 million for the year, primarily due to BrewDog working-capital needs and strategic capital investments.
Tilray Brands Stock Down 4.1%
Tilray Brands stock traded down $0.17 on Wednesday, hitting $3.87. 4,123,625 shares of the stock traded hands, compared to its average volume of 4,216,644. The firm has a market cap of $450.47 million, a P/E ratio of -0.29 and a beta of 1.89. The business’s fifty day simple moving average is $4.74 and its 200 day simple moving average is $6.34. Tilray Brands has a 1 year low of $3.67 and a 1 year high of $23.20. The company has a current ratio of 2.79, a quick ratio of 1.66 and a debt-to-equity ratio of 0.19.
Analysts Set New Price Targets
Get Our Latest Stock Report on TLRY
Hedge Funds Weigh In On Tilray Brands
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Engineers Gate Manager LP purchased a new stake in shares of Tilray Brands in the 4th quarter worth $126,000. Jump Financial LLC purchased a new position in Tilray Brands during the fourth quarter valued at $155,000. Integrated Wealth Concepts LLC grew its holdings in Tilray Brands by 33.8% during the third quarter. Integrated Wealth Concepts LLC now owns 36,977 shares of the company’s stock valued at $64,000 after purchasing an additional 9,341 shares during the period. National Bank of Canada FI grew its holdings in Tilray Brands by 334.5% during the third quarter. National Bank of Canada FI now owns 43,445 shares of the company’s stock valued at $75,000 after purchasing an additional 33,446 shares during the period. Finally, Ameriprise Financial Inc. increased its position in Tilray Brands by 45.4% in the third quarter. Ameriprise Financial Inc. now owns 67,222 shares of the company’s stock worth $116,000 after buying an additional 20,974 shares in the last quarter. Hedge funds and other institutional investors own 9.35% of the company’s stock.
Trending Headlines about Tilray Brands
Here are the key news stories impacting Tilray Brands this week:
- Positive Sentiment: Tilray reported record fiscal 2026 revenue of approximately $915 million and record adjusted EBITDA, highlighting growth across cannabis, beverages, hospitality and wellness. International medical cannabis revenue increased 34% for the year. Tilray fiscal 2026 results
- Positive Sentiment: Management projected fiscal 2027 adjusted EBITDA of $68 million to $75 million, representing anticipated double-digit growth and signaling a focus on margin expansion. Tilray fiscal 2027 EBITDA guidance
- Positive Sentiment: The BrewDog acquisition is expected to expand Tilray’s global beverage platform and provide additional opportunities through brands, hospitality and consumer experiences. The company also reported approximately $235 million in cash, restricted cash and marketable securities, with net debt reduced to about $0.7 million. Tilray diversified platform update
- Neutral Sentiment: Fourth-quarter revenue rose 25.5% year over year to $281.7 million, exceeding estimates near $246 million, while gross profit increased 33.8% to $90.5 million. However, the stronger sales did not translate into bottom-line profitability.
- Negative Sentiment: Tilray posted a fourth-quarter loss of $0.43 per share, substantially worse than the approximately $0.01–$0.02 loss analysts expected and below the prior-year profit. Net loss attributable to common shareholders was $49.6 million, while operating loss widened to $16.5 million. Tilray fourth-quarter earnings report
- Negative Sentiment: Operating cash flow was negative $37.3 million during the quarter, raising concerns about the company’s ability to convert revenue growth into sustainable cash generation. The large EPS miss appears to be the primary reason the stock is under pressure despite the record sales and forward EBITDA outlook. Tilray earnings surprise analysis
Tilray Brands Company Profile
Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.
Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.
See Also
- Five stocks we like better than Tilray Brands
- Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become
- 3 Refiners Benefiting From Oil Volatility and Tight Fuel Supply
- Carrier Earnings Could Send the Stock to a New All-Time High
- 3 Unique AI Software Plays With Strong Analyst Support
Receive News & Ratings for Tilray Brands Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray Brands and related companies with MarketBeat.com's FREE daily email newsletter.
